116 related articles for article (PubMed ID: 15894403)
21. [Malignant pleural mesothelioma].
Gross-Goupil M; Ruffié P
Bull Cancer; 1999 Oct; Suppl 3():43-54. PubMed ID: 10585573
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
[TBL] [Abstract][Full Text] [Related]
23. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
[TBL] [Abstract][Full Text] [Related]
24. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
25. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
27. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
28. Population based epidemiology and prognosis of mesothelioma in Leeds, UK.
Chapman A; Mulrennan S; Ladd B; Muers MF
Thorax; 2008 May; 63(5):435-9. PubMed ID: 18202164
[TBL] [Abstract][Full Text] [Related]
29. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
O'Byrne KJ; Edwards JG; Waller DA
Lung Cancer; 2004 Aug; 45 Suppl 1():S45-8. PubMed ID: 15261433
[TBL] [Abstract][Full Text] [Related]
30. Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
Aigner C; Hoda MA; Lang G; Taghavi S; Marta G; Klepetko W
Eur J Cardiothorac Surg; 2008 Jul; 34(1):204-7. PubMed ID: 18407510
[TBL] [Abstract][Full Text] [Related]
31. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
Ribi K; Bernhard J; Schuller JC; Weder W; Bodis S; Jörger M; Betticher D; Schmid RA; Stupp R; Ris HB; Stahel RA;
Lung Cancer; 2008 Sep; 61(3):398-404. PubMed ID: 18433927
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in mesothelioma staging.
Richards WG
Semin Thorac Cardiovasc Surg; 2009; 21(2):105-10. PubMed ID: 19822281
[TBL] [Abstract][Full Text] [Related]
33. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
Francart J; Vaes E; Henrard S; Legrand C; Baas P; Gaafar R; van Meerbeeck JP; Sylvester R; Robert A
Eur J Cancer; 2009 Sep; 45(13):2304-11. PubMed ID: 19502050
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma.
Matsuzaki Y; Tomita M; Shimizu T; Hara M; Ayabe T; Onitsuka T
Ann Thorac Cardiovasc Surg; 2008 Jun; 14(3):161-5. PubMed ID: 18577894
[TBL] [Abstract][Full Text] [Related]
35. Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results.
Edwards JG; Martin-Ucar AE; Stewart DJ; Waller DA
Eur J Cardiothorac Surg; 2007 May; 31(5):759-64. PubMed ID: 17350854
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
37. [Vinorelbine in patients with malignant pleural mesothelioma--a phase II study].
Ost E; Illiger HJ
Strahlenther Onkol; 2001 Aug; 177(8):440-1. PubMed ID: 11544910
[No Abstract] [Full Text] [Related]
38. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
39. [Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].
Sienel W; Kirschbaum A; Passlick B
Zentralbl Chir; 2008 Jun; 133(3):231-7. PubMed ID: 18563687
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
